Ihosvani Miguel, MD
Endocrinology, Diabetes & Metabolism · Fort Lauderdale, FLNPI 1346400231
Payments from drug & device makers
Across 264 payments — averaging $2654.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- IBSA Institut Biochimique SA$388K
- Eli Lilly$251K
- AstraZeneca$45K
- Currax Pharmaceuticals LLC$12K
- Novo Nordisk$2K
- Lilly USA, LLC$541
- plus $3K from 19 others
Across 2 payments — averaging $4745.44 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly Export S.A. Puerto Rico Branch$8K
- Eli Lilly$1K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| IBSA Institut Biochimique SA | 16 | $387,837 |
| Eli Lilly | 1 | $250,841 |
| AstraZeneca | 15 | $45,283 |
| Currax Pharmaceuticals LLC | 5 | $11,638 |
| Novo Nordisk | 96 | $2,133 |
| Lilly USA, LLC | 28 | $541 |
| Sanofi-aventis U.S. LLC | 12 | $408 |
| AbbVie | 23 | $376 |
| Insulet Corporation | 15 | $329 |
| Dexcom, Inc. | 3 | $228 |
| Amarin Pharma, Inc. | 9 | $218 |
| Boehringer Ingelheim | 8 | $205 |
| Johnson & Johnson | 5 | $167 |
| Bayer | 6 | $140 |
| Abbott | 7 | $127 |
| Amgen | 2 | $126 |
| Corcept Therapeutics | 3 | $71 |
| Madrigal Pharmaceuticals | 2 | $52 |
| Antares Pharma, Inc. | 2 | $42 |
| Astellas Pharma US Inc | 1 | $24 |
| Alvogen Inc | 1 | $24 |
| Ascendis Pharma Endocrinology Inc | 1 | $22 |
| Pfizer | 1 | $20 |
| Mannkind Corporation | 1 | $18 |
| Avion Pharmaceuticals | 1 | $16 |
How this compares
$700,887 in reported general payments places this provider in the 95th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
See all endocrinology, diabetes & metabolism providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other endocrinology, diabetes & metabolism in Fort Lauderdale
- Richard PratleyOrlando$9.2M
- Jose MandryOcoee$9.1M
- Steven SmithOrlando$7.9M
- Barry HorowitzWest Palm Beach$7.1M
- Tina ThethiOrlando$3.8M
- David SuttonJacksonville$3.1M
- Lorena Lewy-AlterbaumHollywood$3.1M
- Mae Sheikh AliJacksonville$2.9M
- James MageeJacksonville$2.7M
- Rodolfo GalindoMiami$2.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.